Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December ...
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 86.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,338 shares of the company's stock after selling 1,194,586 shares during the quarter. Dimensional
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 86.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 188,338 shares of the company's stock after selling 1,194,586 shares during the quarter. Dimensional
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago.
Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation and strengthened its balance sheet through a $340 million convertible note offering.
SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.
Caxton Associates LLP trimmed its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 55.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,035 shares of the company's stock after selling 44,382 shares during the
D.A. Davidson and CO. reduced its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 70.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,750 shares of the company's stock after selling 60,300 shares during the
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Amova Asset Management Americas Inc. lessened its stake in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 18.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,595,370 shares of the company's stock after selling 352,593 shares during the period. Amova Asset Management Americas
Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026. This transaction consisted entirely of directly held shares.
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $250 million aggregate principal amount of notes.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday's session as the company has announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses on testing.
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilution Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Adaptive Biotechnologies also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transaction value of ~$695,000 based on a weighted average price of $17.49 per share. The transaction represented 13.56% of Lo's direct holdings at the time of execution, reducing direct ownership to 250,934 shares.
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Adaptive Biotechnologies NASDAQ: ADPT Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair's Growth Stock Conference.
SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm.
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
